Search clinical trials for: atacand

Total 65 results

AstraZeneca

Completed

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

Hypertension

United States, France, Italy, United Kingdom, Germany, Poland, Ukraine, Belgium, Puerto Rico, Denmark
Augusta University
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Adiposity and Endothelin Receptor Function (END-RF)

Hypertension

United States
Louise Faerch

Completed

Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System

Hypoglycemia | Type 1 Diabetes

Denmark
Takeda

Completed

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

Hypertension

Ukraine, Germany
Göteborg University
Sahlgrenska University Hospital, Sweden

Completed

Expression and Function of the Renin-Angiotensin System in the Esophagus

Barrett's Esophagus

Sweden
AstraZeneca

Completed

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

Hypertension | Left Ventricular Hypertrophy

Korea, Republic of
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Cardiorenal Syndrome (CRS)

United States
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials (DIRECT)

Type 2 Diabetes
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

Congestive Heart Failure
Karin Skov
AstraZeneca; University of Aarhus

Unknown

Danish Hypertension Prevention Project - DHYPP

Hypertension

Denmark
AstraZeneca

Completed

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Congestive Heart Failure
The University of Texas Health Science Center,...

Withdrawn

Candesartan as an Adjunctive Treatment for Bipolar Depression

Bipolar Disorder Depression

United States
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Congestive Heart Failure
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Essential Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure (CANTABILE)

Hypertension | Congestive Heart Failure

Korea, Republic of
University of Texas at Austin

Not yet recruiting

Technology-based Information and Coaching Program Tailored for Asian American Midlife Women Who Are Family Caregivers of Persons With Alzheimer's Disease (TACAD)

Alzheimer Disease

United States
Emory University
National Institute on Aging (NIA)

Completed

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers (CEDAR)

Mild Cognitive Impairment

United States
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials. (DIRECT)

Type 1 Diabetes
Slovak Academy of Sciences

Unknown

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (ADIRAS)

Hypertension

Slovakia
AstraZeneca

Completed

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

Hypertension

United States
AstraZeneca
Takeda

Completed

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France (SISTOLA)

Heart Failure | Cohort Study

France
HK inno.N Corporation

Unknown

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Essential Hypertension

Korea, Republic of
Kaiser Permanente
University of California, Davis

Withdrawn

Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C

Hepatitis C

United States
University of Helsinki
AstraZeneca

Unknown

The Potential of Candesartan to Retard the Progression of Aortic Stenosis (ROCK-AS)

Aortic Valve Stenosis

Finland
Chong Kun Dang Pharmaceutical

Completed

CKD-330 Drug-Drug Interaction Study (Candesartan) (CKD-330(C))

Hypertension

Korea, Republic of
AstraZeneca
Takeda

Completed

Diabetic Retinopathy Candesartan Trials (DIRECT)

Type 1 Diabetes

Denmark, Australia
Montreal Heart Institute
AstraZeneca

Completed

A Pharmacogenomic Study of Candesartan in Heart Failure

Heart Failure

Canada
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Essential Hypertension

Korea, Republic of
University Hospital, Basel, Switzerland

Completed

Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC)

Acute Heart Failure

Spain, Switzerland, Germany, Brazil, Bulgaria
Medical University of Vienna

Completed

RAS Quantification in Patients With Aliskiren or Candesartan (RASQAL)

Hypertension | Proteinuria | Chronic Kidney Disease

Austria
Mayo Clinic

Completed

Angiotensin-II Blockade in Mitral Regurgitation

Mitral Regurgitation

United States
Boryung Pharmaceutical Co., Ltd
Pusan National University Hospital; Ulsan University Hospital; Daegu Catholic... and other collaborators

Completed

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Hypertension

Korea, Republic of
Shin Poong Pharmaceutical Co. Ltd.

Completed

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Yonsei University

Completed

Effect of Candesartan in Alcoholic Liver Fibrosis

Alcoholic Liver Disease

Korea, Republic of
AstraZeneca

Completed

ARIA (Atacand Renoprotection In NephropAthy Pt.) (PCR)

Non-diabetic Nephropathy With Hypertension

Korea, Republic of
AstraZeneca

Completed

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) (HIP)

Hypertension

France, Germany, Poland, Ukraine, Belgium, Italy
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)

Terminated

A Pilot Study of Candesartan as a Treatment for Cocaine Dependence

Cocaine Dependence

United States
AstraZeneca

Completed

Atacand (Candesartan) Real Life Study (Real Life)

Hypertension

Sweden
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Hypertension
GlaxoSmithKline

Completed

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Cardiovascular Disease

India
Pharmtechnology LLC
Altasciences Company, Inc.

Completed

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

Bioequivalence

Canada
HK inno.N Corporation

Unknown

Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan (MACH)

Hypertension

Korea, Republic of
Baim Institute for Clinical Research
Beth Israel Deaconess Medical Center

Completed

Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (CORAL)

Cardiovascular Diseases | Atherosclerosis | Renal Artery Obstruction | Hypertension, Renovascular

United States
Takeda

Terminated

Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure (CANDHEART)

Heart Failure
AstraZeneca

Completed

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg

Hypertension

United Kingdom, Germany, Sweden, Estonia, Lithuania, Poland, Ukraine, Denmark, Netherlands, France, Former Serbia and Montenegro
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)

Completed

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

Substance Abuse | Methamphetamine Dependence | Methamphetamine Abuse

United States
Vanderbilt University

Terminated

Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

Depression | Hypertension

United States
AstraZeneca

Completed

Candesartan Effect in Second Stage Arterial Hypertension (CAESAR)

Stage II Hypertension

Korea, Republic of
AstraZeneca

Completed

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

Hypertension

Russian Federation, Latvia, Romania, Slovakia, Belgium, Malta

3

Subscribe